David Nanchen1, Baris Gencer2, Reto Auer3, Lorenz Räber4, Giulio G Stefanini4, Roland Klingenberg5, Christian M Schmied5, Jacques Cornuz3, Olivier Muller6, Pierre Vogt6, Peter Jüni7, Christian M Matter5, Stephan Windecker4, Thomas F Lüscher5, François Mach2, Nicolas Rodondi8. 1. Department of Ambulatory Care and Community Medicine, University of Lausanne, Rue du Bugnon 44, Lausanne CH-1011, Switzerland david.nanchen@chuv.ch. 2. Division of Cardiology, Geneva University Hospitals, Geneva, Switzerland. 3. Department of Ambulatory Care and Community Medicine, University of Lausanne, Rue du Bugnon 44, Lausanne CH-1011, Switzerland. 4. Department of Cardiology, University Hospital Bern, Bern, Switzerland. 5. Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland. 6. Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland. 7. Department of Clinical Research, Institute of Social and Preventive Medicine and Clinical Trials Unit, University of Bern, Bern, Switzerland. 8. Department of General Internal Medicine, University Hospital of Bern, Bern, Switzerland.
Abstract
AIMS: We aimed to assess the prevalence and management of clinical familial hypercholesterolaemia (FH) among patients with acute coronary syndrome (ACS). METHODS AND RESULTS: We studied 4778 patients with ACS from a multi-centre cohort study in Switzerland. Based on personal and familial history of premature cardiovascular disease and LDL-cholesterol levels, two validated algorithms for diagnosis of clinical FH were used: the Dutch Lipid Clinic Network algorithm to assess possible (score 3-5 points) or probable/definite FH (>5 points), and the Simon Broome Register algorithm to assess possible FH. At the time of hospitalization for ACS, 1.6% had probable/definite FH [95% confidence interval (CI) 1.3-2.0%, n = 78] and 17.8% possible FH (95% CI 16.8-18.9%, n = 852), respectively, according to the Dutch Lipid Clinic algorithm. The Simon Broome algorithm identified 5.4% (95% CI 4.8-6.1%, n = 259) patients with possible FH. Among 1451 young patients with premature ACS, the Dutch Lipid Clinic algorithm identified 70 (4.8%, 95% CI 3.8-6.1%) patients with probable/definite FH, and 684 (47.1%, 95% CI 44.6-49.7%) patients had possible FH. Excluding patients with secondary causes of dyslipidaemia such as alcohol consumption, acute renal failure, or hyperglycaemia did not change prevalence. One year after ACS, among 69 survivors with probable/definite FH and available follow-up information, 64.7% were using high-dose statins, 69.0% had decreased LDL-cholesterol from at least 50, and 4.6% had LDL-cholesterol ≤1.8 mmol/L. CONCLUSION: A phenotypic diagnosis of possible FH is common in patients hospitalized with ACS, particularly among those with premature ACS. Optimizing long-term lipid treatment of patients with FH after ACS is required. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: We aimed to assess the prevalence and management of clinical familial hypercholesterolaemia (FH) among patients with acute coronary syndrome (ACS). METHODS AND RESULTS: We studied 4778 patients with ACS from a multi-centre cohort study in Switzerland. Based on personal and familial history of premature cardiovascular disease and LDL-cholesterol levels, two validated algorithms for diagnosis of clinical FH were used: the Dutch Lipid Clinic Network algorithm to assess possible (score 3-5 points) or probable/definite FH (>5 points), and the Simon Broome Register algorithm to assess possible FH. At the time of hospitalization for ACS, 1.6% had probable/definite FH [95% confidence interval (CI) 1.3-2.0%, n = 78] and 17.8% possible FH (95% CI 16.8-18.9%, n = 852), respectively, according to the Dutch Lipid Clinic algorithm. The Simon Broome algorithm identified 5.4% (95% CI 4.8-6.1%, n = 259) patients with possible FH. Among 1451 young patients with premature ACS, the Dutch Lipid Clinic algorithm identified 70 (4.8%, 95% CI 3.8-6.1%) patients with probable/definite FH, and 684 (47.1%, 95% CI 44.6-49.7%) patients had possible FH. Excluding patients with secondary causes of dyslipidaemia such as alcohol consumption, acute renal failure, or hyperglycaemia did not change prevalence. One year after ACS, among 69 survivors with probable/definite FH and available follow-up information, 64.7% were using high-dose statins, 69.0% had decreased LDL-cholesterol from at least 50, and 4.6% had LDL-cholesterol ≤1.8 mmol/L. CONCLUSION: A phenotypic diagnosis of possible FH is common in patients hospitalized with ACS, particularly among those with premature ACS. Optimizing long-term lipid treatment of patients with FH after ACS is required. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Nadeem Qureshi; Maria Luisa R Da Silva; Hasidah Abdul-Hamid; Stephen F Weng; Joe Kai; Jo Leonardi-Bee Journal: Cochrane Database Syst Rev Date: 2021-10-07
Authors: Emily M Bucholz; Angie Mae Rodday; Katherine Kolor; Muin J Khoury; Sarah D de Ferranti Journal: Circulation Date: 2018-03-26 Impact factor: 29.690
Authors: Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray Journal: Nat Rev Cardiol Date: 2020-01-23 Impact factor: 32.419
Authors: Maria Helane C Gurgel; Renan M Montenegro Junior; Clarisse M Melo Ponte; Tamara Cristina S Sousa; Paulo Goberlanio B Silva; Lucia de Sousa Belém; Frederico Luis Braz Furtado; Lívia A de Araújo Batista; Alexandre C Pereira; Raul D Santos Journal: Lipids Health Dis Date: 2017-11-28 Impact factor: 3.876
Authors: Reto Auer; Baris Gencer; Rodrigo Tango; David Nanchen; Christian M Matter; Thomas Felix Lüscher; Stephan Windecker; François Mach; Jacques Cornuz; Jean-Paul Humair; Nicolas Rodondi Journal: BMJ Open Date: 2016-09-20 Impact factor: 2.692